OncoMatch/Clinical Trials/NCT06860971
A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma
Is NCT06860971 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies AL2846 Capsules for thyroid cancer.
Treatment: AL2846 Capsules — This study aims to demonstrate that, in subjects with locally advanced or metastatic iodine - refractory differentiated thyroid cancer who have failed previous VEGFR - targeted therapy, AL2846 can significantly prolong progression - free survival (PFS) compared with placebo.
Check if I qualifyExtracted eligibility criteria
Cancer type
Thyroid Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: VEGFR inhibitor
Disease progression (per RECIST 1.1) after receiving no more than 2 lines (no more than 3 types) lines of Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR TKI) therapy
Cannot have received: other anti-tumor clinical trial drugs
Subjects who have participated in and used other anti-tumor clinical trial drugs within 4 weeks before randomization.
Lab requirements
Blood counts
Hemoglobin (HGB) ≥90 g/L; Absolute neutrophil count (NEUT) ≥1.5×10⁹/L; Platelet count (PLT) ≥90×10⁹/L
Kidney function
Creatinine clearance (CCR) ≥50 mL/min
Liver function
Total bilirubin (TBIL) ≤1.5×ULN; ALT and AST ≤2.5×ULN
Laboratory parameters: HGB ≥90 g/L; NEUT ≥1.5×10⁹/L; PLT ≥90×10⁹/L; TBIL ≤1.5×ULN; ALT and AST ≤2.5×ULN; CCR ≥50 mL/min; PT, APTT, INR ≤1.5×ULN (without anticoagulation therapy); ALB ≥30 g/L (no albumin infusion within 7 days prior to screening).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify